AstraZeneca PLC AZN NYSE

AstraZeneca PLC (AZN) reported moderate year-over-year revenue growth of +6.8% through 2025-12 (TTM revenue vs prior-year TTM). Net income showed exceptional earnings expansion of +31.6% YoY, reaching $2.3B in the latest quarter. The net profit margin is 15%, which is high. The company has maintained profitability in all 4 quarters. The gross margin is 82% (high), up 0.6pp vs the prior year. With a $317B market cap, MOAT composite score of 90/100 (strong competitive position).

Criteria proven by this page:

• GROWTH (90/100, Pass) — proving strong growth momentum
• PAST (100/100, Pass) — proving consistent earnings. Looking at the full 36-year annual history, the company was profitable in 36 of 36 years — a perfect long-term track record
• INCOME (70/100, Pass) — proves strong profitability and pricing power
• MOAT (90/100, Pass) — strong gross margins and market scale prove a durable competitive advantage

Overall SharesGrow Score: 64/100 with 4/7 criteria passed.